JP2023537002A5 - - Google Patents
Info
- Publication number
- JP2023537002A5 JP2023537002A5 JP2023507973A JP2023507973A JP2023537002A5 JP 2023537002 A5 JP2023537002 A5 JP 2023537002A5 JP 2023507973 A JP2023507973 A JP 2023507973A JP 2023507973 A JP2023507973 A JP 2023507973A JP 2023537002 A5 JP2023537002 A5 JP 2023537002A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- antigen
- antibody
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025250936A JP2026034608A (ja) | 2020-08-06 | 2025-12-15 | 抗クローディン１８．２多重特異性抗体及びそれらの使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063061895P | 2020-08-06 | 2020-08-06 | |
| US63/061,895 | 2020-08-06 | ||
| US202063074582P | 2020-09-04 | 2020-09-04 | |
| US63/074,582 | 2020-09-04 | ||
| US202163144657P | 2021-02-02 | 2021-02-02 | |
| US63/144,657 | 2021-02-02 | ||
| PCT/US2021/044801 WO2022032004A2 (en) | 2020-08-06 | 2021-08-05 | Anti-claudin 18.2 multi-specific antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025250936A Division JP2026034608A (ja) | 2020-08-06 | 2025-12-15 | 抗クローディン１８．２多重特異性抗体及びそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023537002A JP2023537002A (ja) | 2023-08-30 |
| JP2023537002A5 true JP2023537002A5 (enExample) | 2024-08-13 |
| JP7792395B2 JP7792395B2 (ja) | 2025-12-25 |
Family
ID=80117669
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507973A Active JP7792395B2 (ja) | 2020-08-06 | 2021-08-05 | 抗クローディン１８．２多重特異性抗体及びそれらの使用 |
| JP2025250936A Pending JP2026034608A (ja) | 2020-08-06 | 2025-12-15 | 抗クローディン１８．２多重特異性抗体及びそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025250936A Pending JP2026034608A (ja) | 2020-08-06 | 2025-12-15 | 抗クローディン１８．２多重特異性抗体及びそれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230279152A1 (enExample) |
| EP (1) | EP4192879A4 (enExample) |
| JP (2) | JP7792395B2 (enExample) |
| KR (1) | KR20230070203A (enExample) |
| WO (2) | WO2022032004A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020023702A1 (en) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| CA3165927A1 (en) | 2020-01-11 | 2021-07-15 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| JP2025511493A (ja) | 2022-05-31 | 2025-04-16 | エルジー エナジー ソリューション リミテッド | リチウム二次電池用複合固体電解質及びこの製造方法 |
| CN118307678A (zh) * | 2023-06-07 | 2024-07-09 | 北京义翘神州科技股份有限公司 | 一种抗cldn18_2的抗体 |
| KR20260028757A (ko) * | 2023-06-08 | 2026-03-04 | 안텐진 바이올로직스 리미티드 | 항-cldn18.2 항체 및 이의 진단적 용도 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2436397B1 (en) * | 2009-05-29 | 2017-05-10 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition containing antagonist of egf family ligand as component |
| JP2017531642A (ja) * | 2014-10-03 | 2017-10-26 | マサチューセッツ インスティテュート オブ テクノロジー | エボラ糖タンパク質に結合する抗体およびその使用 |
| HK1250723A1 (zh) * | 2015-05-29 | 2019-01-11 | F. Hoffmann-La Roche Ag | 人源化抗埃博拉病毒糖蛋白抗体和使用方法 |
| JP6768011B2 (ja) * | 2015-06-23 | 2020-10-14 | バイエル ファーマ アクチエンゲゼルシャフト | キネシンスピンドルタンパク質（ｋｓｐ）阻害剤の抗ｃｄ１２３抗体との抗体薬物複合体 |
| US11059887B2 (en) * | 2018-05-18 | 2021-07-13 | Lanova Medicines Limited Company | Anti-claudin 18.2 antibodies and uses thereof |
| WO2019242505A1 (zh) * | 2018-06-17 | 2019-12-26 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用 |
| US12054543B2 (en) * | 2018-07-25 | 2024-08-06 | Accurus Biosciences, Inc. | CLDN 18.2-specific monoclonal antibodies and methods of use thereof |
| WO2020025792A1 (en) * | 2018-08-03 | 2020-02-06 | Amgen Research (Munich) Gmbh | Antibody constructs for cldn18.2 and cd3 |
| US10522488B1 (en) * | 2018-10-31 | 2019-12-31 | Taiwan Semiconductor Manufacturing Company, Ltd. | Patterning polymer layer to reduce stress |
| CN109762067B (zh) * | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
-
2021
- 2021-08-05 JP JP2023507973A patent/JP7792395B2/ja active Active
- 2021-08-05 EP EP21853256.2A patent/EP4192879A4/en active Pending
- 2021-08-05 WO PCT/US2021/044801 patent/WO2022032004A2/en not_active Ceased
- 2021-08-05 WO PCT/US2021/044800 patent/WO2022032003A2/en not_active Ceased
- 2021-08-05 US US18/019,728 patent/US20230279152A1/en active Pending
- 2021-08-05 KR KR1020237007877A patent/KR20230070203A/ko active Pending
-
2025
- 2025-12-15 JP JP2025250936A patent/JP2026034608A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023537002A5 (enExample) | ||
| Paul et al. | Cancer therapy with antibodies | |
| US12384850B2 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| Xu et al. | Retargeting T cells to GD2 pentasaccharide on human tumors using bispecific humanized antibody | |
| US12029761B2 (en) | Guidance and Navigation Control proteins and method of making and using thereof | |
| JP2022541435A5 (enExample) | ||
| Zekri et al. | An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers | |
| RU2017145150A (ru) | Антитело против pdl-1, его фармацевтическая композиция и применение | |
| JP2022546572A5 (enExample) | ||
| JP2024530166A5 (enExample) | ||
| CN114634569A (zh) | 高亲和力b7-h6抗体和抗体片段 | |
| JP2022525435A5 (enExample) | ||
| JP2023523584A5 (enExample) | ||
| Guo et al. | Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment | |
| JP2020523029A5 (enExample) | ||
| JP2025508066A (ja) | 目的としたｔ細胞活性化のためのｃｄ２８二重特異性抗体 | |
| Wang et al. | An optimal antitumor response by a novel CEA/CD3 bispecific antibody for colorectal cancers | |
| JP7592712B2 (ja) | ガイダンス及びナビゲーションコントロールタンパク質、その製造方法及び使用方法 | |
| CN111065409A (zh) | Strep-tag特异性结合蛋白及其用途 | |
| Holliger et al. | Engineering antibodies for the clinic | |
| US20240141043A1 (en) | Bispecific antibody that binds to cd3 and a fluorophore | |
| Jachimowicz et al. | Multi-specific antibodies for cancer immunotherapy | |
| WO2022093694A1 (en) | Polypeptides targeting hpv peptide-mhc complexes and methods of use thereof | |
| US20230340119A1 (en) | Composition of triax antibodies and method of making and using thereof | |
| JP2024540863A5 (enExample) |